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Prostate cancer will develop chemoresistance following a period of chemotherapy. This is due, in part, to the acquisition of
antiapoptoticpropertiesbythecancercellsand,therefore,developmentofnovelstrategiesfortreatmentisofcriticalneed.Here,
we attempt to clarify the role of the antiapoptotic molecule galectin-3 in prostate cancer cells using siRNA and antagonist
approaches. The data showed that Gal-3 inhibition by siRNA or its antagonist GCS-100/modiﬁed citrus pectin (MCP) increased
cisplatin-induced apoptosis of PC3 cells. Recent studies have indicated that cisplatin-induced apoptosis may be mediated by
calpain, a calcium-dependent protease, as its activation leads to cleavage of androgen receptor into an androgen-independent
isoforminprostatecancercells.Thus,weexaminedwhethercalpainactivationisassociatedwiththeGal-3functionofregulating
apoptosis. Here, we report that Gal-3 inhibition by siRNA or GCS-100/MCP enhances calpain activation, whereas Gal-3
overexpression inhibits it. Inhibition of calpain using its inhibitor and/or siRNA attenuated the proapoptotic effect of Gal-3
inhibition, suggesting that calpain activation may be a novel mechanism for the proapoptotic effect of Gal-3 inhibition. Thus,
a paradigm shift for treating prostate cancer is suggested whereby a combination of a non-toxic anti-Gal-3 drug together with
a toxic chemotherapeutic agent could serve as a novel therapeutic modality for chemoresistant prostate cancers.
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Prostate cancer is the most common cancer among men
in Western countries. A large number of patients already
show metastatic disease at the time of diagnosis. At this
stage, prostate cancer is incurable and its growth can only be
slowed by hormone deprivation or chemotherapy. Unfortu-
nately, most cases eventually become hormone refractory
and chemoresistant.
1 Therefore, it is important to understand
the mechanisms for chemoresistance of prostate cancer, and
discover new targets to retrigger the sensitivity of prostate
cancer cells to chemotherapeutic drugs.
Galectin-3 (Gal-3), a 31kD carbohydrate-binding protein, is
involved in cell growth, cell adhesion, invasion, apoptosis and
cancer cell metastasis.
2–4 Increased expression of Gal-3 has
been reported during the progression of several human
tumors.
5–7 In prostate cancer, Gal-3 protein expression may
be decreased compared with normal prostate and prostatic
intraepithelial neoplasia.
8,9 Using differential immunohisto-
chemistry, we recently reported that although the expression
level of intact Gal-3 decreased, its cleavage could be
associated with the progression of prostate cancer.
10 Others
have found that loss of Gal-3 expression in early stages of
prostate cancer tissues and low aggressive prostate cancer
cell lines was due to the heavy methylation of Gal-3
promoter.
11,12 In addition, Gal-3 knockdown resulted in
reduced cell invasion, cell proliferation, and tumorigenicity of
PC3cells.
10Resistancetoapoptosisisoneofthehallmarksof
cancercells.TheantiapoptoticfunctionofGal-3hasbeenwell
demonstratedinavarietyofhumancancers,suchasbreast,
13
ovarian,
14 and bladder.
15 However, data regarding the mode
of action of Gal-3 in resistance to drug-induced apoptosis of
human prostate cancer cells are not yet determined, as only a
single study reported that overexpression of Gal-3 in Gal-3
null LNCaP cells resulted in the acquisition of resistance
to anticancer drug-induced apoptosis.
16 Another human
prostate cancer cell line PC3, which is not sensitive to
anticancer drugs, has high expression level of endogenous
Gal-3. Therefore, we hypothesized that Gal-3 expression may
contribute, in part, to the chemoresistance of prostate cancer,
and that inhibition of Gal-3 using siRNA and/or its antagonist
may salvage the sensitivity of prostate cancer cells to chemo-
therapy. GCS-100 AKA, modiﬁed citrus pectin (MCP), which
isthepH-/temperature-modiﬁedformofcitruspectin(CP),isa
highly complex branched polysaccharide rich in galactoside
residues. CP is water insoluble and is unable to interact
with Gal-3, but MCP is water soluble and acts as a ligand for
Gal-3 competing with its association to natural ligands.
17–19
It was reported that GSC-100/MCP could inhibit the lung
colonization,
17 cell–cell and cell–matrix interaction of B16-F1
melanoma cells.
18 Oral intake of MCP could inhibit the lung
metastasis of prostate cancer cells in rat.
19 GCS-100/MCP
feeding inhibited the tumor growth, angiogenesis, and
spontaneous metastasis of human breast and colon carcino-
ma cells in nude mice.
20 Jackson et al reported that MCP
induced apoptosis in human prostate cancer cells.
21 It was
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Cisplatin, a widely used chemotherapeutic agent, is highly
effective against several cancers, including testicular, breast,
ovarian, bladder, and lung cancers. Late stage prostate
cancer is resistant to cisplatin treatment because of the
development of chemoresistance.
23 Cisplatin treatment in
Gal-3-expressing PC3 cells could serve as a model to study
the relationship between Gal-3 expression and chemoresis-
tance of prostate cancer cells. Two major apoptotic pathways
have been deﬁned: death receptor apoptotic pathway leading
to caspase-8 activation and mitochondrial apoptotic pathway
leading to cytochrome c release and caspase-9 activation.
24
Both pathways activate downstream effecter caspases
(caspase-3, -6, and -7) that lead to apoptosis features. Of
note, in prostate cancer, it was reported that apoptosis can
be mediated by calpain activation.
25,26 Calpain is a family
of calcium-dependent proteases, calpain 1 and 2 are major
family members. Studies suggest that apoptosis may be
mediated by calpain activation in response to the alteration of
mitochondria-mediated calcium homeostasis.
27 Calpain acti-
vation may lead to the cleavage of androgen receptor into an
androgen-independent isoform in apoptotic prostate cancer
cells.
28 Here, we report that inhibition of Gal-3 using siRNA or
its antagonist GCS-100/MCP increased cisplatin-induced
apoptosis of PC3 cells, and calpain activation contributed to
the proapoptotic effect of Gal-3 inhibition.
Results
Gal-3 knockdown sensitized PC3 cells to chemo-
therapeutic drug-induced apoptosis. RNAi technique
was used to knockdown Gal-3 expression, and the
expression levels of Gal-3 protein in two transfectants were
sharply reduced (Figure 1a). Furthermore, the lower panel
shows that Gal-3 protein mainly localized in the cytoplasm of
PC3 cells. Figure 1b shows that Gal-3 knockdown boosts
apoptosis of PC3 cells treated by 50mM of cisplatin or 6nM of
docetaxel. The proapoptotic effect of Gal-3 knockdown was
further conﬁrmed by detection of 89kD poly (ADP-ribose)
polymerase (PARP), DNA laddering assay, cell viability
assay, and DNA content assay by ﬂow cytometry. PARP, a
113kD protein, is cleaved to fragments of B89 and 24kD
during apoptosis,
29 and detection of 89kD PARP has served
as a marker of apoptosis.
30 As shown in Figure 1c, compared
with VC cells, signiﬁcantly increased levels of 89kD PARP
were detected in siGal3-11 and siGal3-19 after cisplatin
treatment. Figure 1d shows more DNA fragmentation was
detected in Gal-3 knockdown cells after cisplatin treatment.
Cell viability assay also showed that fewer cells survived
in siGal3-11 (40%±3.6) and siGal3-19 (26.6%±4.5) clones
compared with VC cells (53.8%±5.8) after cisplatin treat-
ment (Figure 1e). In Figure 1f, cisplatin treatment resulted
in more sub-G1 region cells, indicating more apoptotic cells
in Gal-3 knockdown clones.
Gal-3 knockdown potentiated cisplatin-induced caspase
activation. Western blot analysis of the expression of
active caspase-3 (Figure 2ai) and caspase-3 activity assay
(Figure 2aii) suggested that Gal-3 knockdown transfectants
showed a higher level of caspase-3 activation than control
cells after cisplatin treatment. As shown in Figure 2b,
cisplatin treatment resulted in caspase-9 activation in Gal-3
knockdown transfectants, but no caspase-9 activation was
observed in control cells. The expression of Gal-3 protein is
not changed by cisplatin treatment (Figure 2c).
Gal-3 knockdown facilitated mitochondrial apoptotic
events. Mitochondria were stained with mitochondrion-
selective probe MitoTracker Red CMXRos. As observed in
untreated cells (Figures 3A, a, b, and c), the mitochondria
in cisplatin-treated VC cells (Figures 3A, d) retained the
ﬁbrillar ﬂuorescence pattern and strong staining. However,
6h of cisplatin treatment resulted in the loss of mitochondrial
structure and reduced staining in siGal3-11 and siGal3-19
cells (Figures 3A, e and f), as MitoTracker Red dye is
washed out of cells and cannot be sequestered once mito-
chondrial membrane potential is lost. Our results also show
that levels of cytosolic cytochrome c in Gal-3 knockdown
cells were elevated up to 3.8-fold compared with that in
VC cells after cisplatin treatment (Figure 3B). To explore
what contributes to Gal-3-associated mitochondrial protec-
tion, western blot analysis of Bcl-2 family members was
performed and results show that cisplatin treatment
increased Bcl-2 expression in Gal-3-expressing VC cells;
however, in Gal-3 knockdown cells, Bcl-2 expression was not
affected by cisplatin treatment and still remained at the basic
level as untreated cells. The expression level of Bcl-XL or
Bax between control cells and Gal-3 knockdown transfec-
tants did not show obvious differences (Figure 3C).
Loss of Gal-3 expression enhanced cisplatin-induced
calpain activation. Recent studies have demonstrated
that activation of calpain could mediate apoptosis.
25,26
We examined calpain activation by western blot analysis
of its substrate spectrin aII and zymography analysis of its
substrate casein. Spectrin aII is an universally expressed
membrane-associated cytoskeletal protein.
31 Full-length
Figure 1 Gal-3 knockdown enhanced chemotherapeutic drug-induced apoptosis of PC3 cells. (a) Gal-3 expression and localization were analyzed by western blot
analysis (upper) and immunoﬂuorescence (400 magniﬁcation) (lower). (b) The effect of Gal-3 knockdown on caspase-3 activation induced by different concentrations
of drugs. Cells were treated with docetaxel (2nM or 6nM) and cisplatin (25mMo r5 0mM) for 48h. Numbers represent the relative intensity of active caspase-3 normalized to
b-actin.Thevaluesof VCcellswereset as ‘‘1’’.(c)Theeffect ofGal-3knockdownon PARPcleavageinducedbycisplatin(50mM) for indicatedtimes.Numbersrepresentthe
relativeintensityof89kDPARPnormalizedtob-actin.ThevaluesofVCcellsweresetas‘‘1’’.DNAladderingassay(d),cellviabilityassaybyMTT(e),andDNAcontentassay
by ﬂow cytometry (f) conﬁrmed the proapoptotic effect of Gal-3 knockdown. Cells were treated with cisplatin (50mM) for 24h. In (e), columns (n¼3), mean; bars, ±S.D.
*Po0.05; **Po0.01 comparedwith VCcells. In (f), the percentagerepresentsapoptoticcells in sub-G1 region. **Po0.01; ***Po0.001 compared with VC cells. P, parental
cells; VC, cells transfected with non-target vector; siGal3-11 and siGal3-19, Gal-3 knockdown clones. Data are representative of three independent experiments
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Cell Death and Diseasespectrin aII can be cleaved into a 150kD fragment
speciﬁcally by calpain
32 or a 120kD fragment speciﬁcally
by caspase-3.
33 Figure 4A showed that cisplatin treatment
did not change the expression level of either calpain 1 or 2.
In Figure 4B, cisplatin treatment for 12h resulted in elevated
levels of 150kD fragments of spectrin in siGal3-11 (3.4-fold)
and siGal3-19 (3.2-fold). Interestingly, 24h after cisplatin
treatment, 150kD fragments in Gal-3 knockdown cells
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Cell Death and Diseasebecame slightly lower than that in VC cells, it may be possible
that 150kD fragments can be further cleaved by active
caspase-3 into 120kD fragments. In addition, casein
zymography showed that 12h cisplatin treatment resulted
in higher levels of calpain 2 activity in siGal3-11 (4.9-fold) and
siGal3-19 (5.1-fold) than that in VC cells (Figure 4C). Our
data also indicate that Gal-3 knockdown increased cisplatin-
induced intracellular calcium levels (Figure 4D). To conﬁrm
the regulatory effect of Gal-3 on calpain activation, we
also examined the activation of calpain in LNCaP cells. It was
reported that Gal-3 overexpression reduced cisplatin-
induced apoptosis of LNCaP cells.
16 Here, as shown in
Figure 5c, 150kD fragment of spectrin indicating calpain
activation was detected in Gal-3 null VC cells after cisplatin
treatment, but not in Gal-3 overexpressing clones. Cisplatin
treatment resulted in higher level of calpain activity in Gal-3
null VC cells compared with Gal-3 overexpressing clones
(Figure 5d). The expression levels of calpain 2 in control cells
and Gal-3 overexpressing clones were not changed by
cisplatin (Figure 5b).
Calpain activation contributed to the proapoptotic effect
of Gal-3 knockdown. Two independent methodologies
(speciﬁc calpain inhibitor PD150606 and siRNA) were
employed to inhibit calpain activation. Figure 6ai indicates
that cisplatin-induced calpain activation in Gal-3 knockdown
cells was attenuated to 10% by 20mM PD150606. This
dosage of PD150606 also attenuated cisplatin-induced
caspase-3 activation (o70% in siGal3-11 and o60% in
siGal3-19) and cleavage of PARP (o70% in siGal3-11 and
o80% in siGal3-19) in Gal-3 knockdown cells, but had no
effect on cytochrome c release or caspase-9 activation
(Figure 6aii), suggesting that calpain activation might be
a novel mechanism for the proapoptotic effect of Gal-3
knockdown through inducing caspase-3 activation in a
mitochondria-independent way. Furthermore, we trans-
fected cells with siRNAs targeting calpain 1 or 2 to further
understand which isoform exerts the effect. Transfection of
calpain 1 siRNA had no effect on apoptosis. Figure 6bi
showed the inhibitory efﬁciency of siRNA targeting calpain 2.
Transfection of calpain 2 siRNA attenuated the enhanced
caspase-3 activation (o60%) and PARP cleavage (o70% in
siGal3-11 and o80% in siGal3-19) in Gal-3 knockdown cells
(Figure 6bii), suggesting that calpain 2 activation mediated
the proapoptotic effect of Gal-3 knockdown in PC3 cells.
Inhibition of Gal-3 by GCS-100/MCP-enhanced cells’
sensitivity to cisplatin in a calpain-dependent way. To
conﬁrm the association of Gal-3 expression with resistance
to cisplatin, GCS-100/MCP was used to block the functions
of Gal-3. GCS-100/MCP sensitized Gal-3-expressing PC3
cells to cisplatin-induced cell death (Figure 7ai). Compared
with cisplatin only, the expression levels of active caspase-3
elevated up to 4.6-fold in cells treated with cisplatin and
GCS-100/MCP together (Figure 7aii). These results indi-
cated that GCS-100/MCP may confer cells’ sensitivity to
cisplatin-induced apoptosis through blocking Gal-3 functions.
Figure 7bi showed that the expression levels of spectrin
150kD fragments in cells treated with GCS-100/MCP and
cisplatin together were up to 3.2-fold higher than cells treated
with cisplatin only, this was conﬁrmed with casein zymo-
graphy (Figure 7bii). In Figure 7c, enhanced cisplatin-
induced apoptosis by GCS-100/MCP was attenuated by
calpain 2 siRNA, suggesting that the proapoptotic effect
of Gal-3 inhibition through GCS-100/MCP was mediated by
calpain activation.
Discussion
Prostatecancer isthe secondleading causeof cancer-related
death in Western countries.
34 The early stages of prostate
cancer can be effectively treated by androgen ablation
Figure 2 Gal-3 knockdown enhanced cisplatin-induced activation of caspase-3
and -9. Cells were treated with 50mM cisplatin for indicated times. Western blot
analysis of the expression levels of active caspase-3 (ai) and caspase-9 (bi).
Numbers represent the relative intensity of active caspase-3 normalized to b-actin.
The values of VC cells were set as ‘1’. (aii) caspase-3 activity assay and (bii)
caspase-9 activity assay. Columns (n¼3), mean; bars, ±S.D. *Po0.05;
**Po0.01; ***Po0.001 compared with VC cells. (c) Western blot analysis of
Gal-3 expression. Data are representative of three independent experiments
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Cell Death and Diseasetherapy. However, most cases of prostate cancer eventually
relapse to an androgen refractory state at which chemo-
therapy is the ﬁnal choice to slow down the growth of prostate
cancer. Unfortunately, chemotherapy is not effective because
cancer cells develop resistance to drugs. Therefore, it is
imperative to explore novel therapeutic targets to improve the
sensitivity of prostate cancer cells to chemotherapy.
Gal-3, a b-galactoside-binding protein, regulates multiple
biological functions, including regulating cell proliferation,
invasion, tumorigenicity, and apoptosis. It was reported that
decreased expression and increased cleavage of Gal-3 are
associated with the development and progression of human
prostate cancer.
8–10 Exogenously added recombinant Gal-3
exhibits proapoptotic activity in human T leukemia cells,
35
whereas intracellular Gal-3 imparts resistance to apoptosis
in many cancer cells. For example, overexpression of Gal-3
protected human breast cancer cell line BT-549 from apop-
tosis through inducing cell cycle arrest.
36 Overexpression
of Gal-3 inhibits tumor necrosis factor-related apoptosis-
inducing ligand-induced apoptosis in human bladder carcino-
ma cells.
15 However, the association of Gal-3 with the
resistance to drug-induced apoptosis of prostate cancer cells
is not yet well documented. It was reported that Gal-3
overexpression in Gal-3 null LNCaP cells resulted in the
acquisition of resistance to anticancer drug-induced apopto-
sis.
16 On the other hand, PC3 cells express high level of
endogenous Gal-3 and are not sensitive to chemotherapeutic
agents. The opposite properties between LNCaP and PC3
cells lead us to hypothesize that expression of Gal-3 might
partly be responsible for the resistance to drug-induced
apoptosis of prostate cancer cells.
To testify our hypothesis, we studied the effect of inhibition
of Gal-3 on cisplatin-induced apoptosis using two approa-
ches: Gal-3 knockdown by siRNA and blockage of Gal-3
functions using GCS-100/MCP. GCS-100/MCP was reported
to have inhibitory effects on tumor growth, homotypic and
heterotypic cell adhesion of cancer cells, tumor metastasis,
and induced apoptosis of cancer cells by acting as an
antagonist of Gal-3.
17–21 As reported, GCS-100/MCP was
already used in clinical trials for treating various tumors.
37 Our
results showed that Gal-3-expressing cells were resistant
to chemotherapeutic drug-induced apoptosis as compared
with Gal-3 knockdown cells, indicating that Gal-3 expression
may be associated with chemoresistance of PC3 cells and
Figure 3 Gal-3 knockdown enhanced cisplatin-induced mitochondrial apoptotic events. Cells were treated with 50mM cisplatin for indicatedtimes. (A) Fluorescent image
of mitochondria staining (400 magniﬁcation). Mitochondria were stained as indicated in Materials and Methods. a–f, mitochondria staining with MitoTracker Red CMXRos;
a0–f0, nuclear staining with 40, 6-diamidino-2-phenylindole; a00–f00, merged image. a–a00 and d–d00, VC; b–b00 and e–e00, siGal3-11; c–c00 and f–f00, siGal3-19. Lower panel is
the quantiﬁcation of ﬂuorescent density of mitochondria staining using Adobe Photoshop CS3 extended software (Adobe Systems Incorporated, San Jose, CA, USA).
***Po0.001, compared with VC cells. Western blot analysis of cytochrome c release (B) and Bcl-2 family members (C). Numbers represent the relative intensities of
cytochrome c and Bcl-2 normalized to b-actin. The values for cytochrome c and Bcl-2 of VC cells were set as ‘‘1’’. Data are representative of three independent experiments
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Cell Death and Diseaseinhibition of Gal-3 may render the retrieval of chemosensitivity
of prostate cancer cells. Furthermore, we determined that the
increased apoptosis mediated by Gal-3 knockdown was due
tomitochondrialdamage,leadingtocytochromecreleaseand
activation of caspase-9. This is consistent with the previous
study on LNCaP cells.
16 The Bcl-2 family consists of both
proapoptotic (Bax and Bak) and antiapoptotic (Bcl-2 and
Bcl-XL) members.
38 Here, we report that Gal-3 knockdown
alters the expression level of neither Bcl-XL nor Bax. In Gal-3-
expressing VC cells, cisplatin treatment resulted in upregula-
tion of Bcl-2, which is the protective factor for mitochondrial
integrity. However, in Gal-3 knockdown cells, the expression
levels of Bcl-2 after cisplatin treatment remained at the basic
level as observed in untreated cells, suggesting that Gal-3
knockdown prevents Bcl-2 upregulation induced by cisplatin
and consequent protection of mitochondrial integrity. To
conﬁrm the effect of Gal-3 knockdown on apoptosis, GCS-
100/MCP was used to block the function of Gal-3, and our
results suggest that GCS-100/MCP may enhance cells’
sensitivity to cisplatin through the inhibition of Gal-3.
In addition to the death receptor and mitochondrial
apoptotic pathways, increasing evidence indicates the asso-
ciation of calpain activation with apoptosis of prostate cancer
cells.
25,26 Calpain is a family of calcium-dependent proteases
that are functionally active as a heterodimer composed of
a small regulatory subunit and one large catalytic subunit.
Calpain1(requiresmicromolarlevelsofcalciumforactivation)
and 2 (requires millimolar levels of calcium for activation)
are the major members of this family and have been studied
most extensively. PC3 cells can express both calpain
1 and 2. It has been reported that calpain activation mediated
cisplatin-induced apoptosis in lung cancer cells,
39 and calpain
activation could be triggered in response to alteration of
mitochondria-mediated calcium homeostasis.
27 Studies also
showed that cisplatin-induced calpain activation mediated
androgen receptor breakdown in apoptotic prostate cancer
cells.
28 Our results demonstrated that non/low Gal-3-expres-
sing cells exhibited higher level of calpain activity than high
Gal-3-expressing cells in response to cisplatin treatment
(Figures 4 and 5), suggesting that calcium-dependent calpain
activation may be a novel mechanism for the proapoptotic
effect of Gal-3 knockdown on cisplatin-induced apoptosis in
prostate cancer cells. Using speciﬁc inhibitor PD150606
and/or siRNAs targeting calpain 1 or 2, we revealed that
cisplatin-induced PARP cleavage and caspase-3 activation
in Gal-3 knockdown cells were attenuated by PD150606 or
calpain 2 siRNA, neither caspase-9activation nor cytochrome
c release was affected, which indicates that calpain activation
(speciﬁcally calpain 2 activation) mediated proapoptotic
effect of Gal-3 knockdown on cisplatin-induced apoptosis in
amitochondria-independentwayinprostatecancercells.This
was further conﬁrmed by using GCS-100/MCP. GCS-100/
MCP treatment enhanced cisplatin-induced calpain activation
through blocking the functions of Gal-3, and the proapoptotic
effect of Gal-3 inhibition by GCS-100/MCP was mediated by
calpain 2 activation.
Our study suggested that Gal-3 expression contributes,
in part, to the chemoresistance of prostate cancer cells, and
Gal-3 inhibition by siRNA or GCS-100/MCP could resensitize
prostate cancer cells to cisplatin treatment through mitochon-
drial apoptotic pathway and calpain activation. To conclude,
the data suggest a paradigm shift in treating prostate cancer
Figure 4 Gal-3 knockdown enhanced cisplatin-induced calpain activation in PC3 cells. Cells were treated with 50mM cisplatin for indicated times. (A) Western blot
analysisshowedthatcisplatindidnotchangetheexpressionlevelsofcalpain1and2.(B)Calpainactivityasrepresentedbywesternblotanalysisofspectrin150kDfragment.
Numbers represent the relative intensities of spectrin 150kD and spectrin 120kD normalized to b-actin. The values of VC cells were set as ‘‘1’’. (C) Casein zymography to
detect calpain activity. Puriﬁed recombinant rat calpain 2 was used as the positive control. Numbers represent the intensity of calpain 2. The value of VC cells was set as ‘‘1’’.
(D) Fluorescent image of cytosolic calcium levels (200 magniﬁcation). Cells were stained with Fluo-4 AM as indicated in Materials and Methods. a and a0, VC; b and b0,
siGal3-11; c and c0, siGal3-19. Data are representative of three independent experiments
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Cell Death and Diseasewhereby a combination therapy of a non-toxic polysaccharide
Gal-3 antagonist together with a toxic chemotherapeutic
agent could serve as a novel therapeutic modality for
chemorefractory prostate cancers.
Materials and Methods
Materials and antibodies. Monoclonal rat anti-Gal-3 antibody was isolated
from the supernatant of hybridoma (catalog number: TIB-166, American Type
Culture Collection, Rockville, MD, USA); cisplatin, docetaxel, thiazolyl blue
tetrazolium bromide (MTT), mouse anti-b-actin and anti-b-tubulin were
purchased from Sigma Chemicals (St. Louis, MO, USA); ﬂuorogenic caspase
substratesAc-DEVD-AMCandAc-LEHD-AFC,calpain-speciﬁcinhibitorPD150606,
and mouse anti-Bcl-XL were purchased from Calbiochem (San Diego, CA, USA);
MitoTracker red CMXRos and Fluo-4 AM were purchased from Invitrogen
(Carlsbad, CA, USA); siRNAs duplex targeting calpain 1, 2 and non-target control
siRNA, rabbit anti-caspase-3, rabbit anti-caspase-9, and mouse anti-spectrin aII
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); mouse
anti-PARP(Biomol,PlymouthMeeting,PA,USA);FITCrabbitanti-activecaspase-3
(BD Biosciences, San Diego, CA, USA); mouse anti-cytochrome c (Zymed
Laboratories, South San Francisco, CA, USA); rabbit anti-Bcl-2, anti-Bax and
anti-calpain 2 (Cell Signaling Technology, Beverly, MA, USA).
Preparation of GCS-100/MCP. CP was purchased from Sigma Chemicals.
Temperature modiﬁcation of CP was performed as follows: CP solution (1.3%) was
autoclaved for 1h, cooled to room temperature, centrifuged at 10000r.p.m. for
10min. Collected supernatant was precipitated with two volumes of absolute
ethanol and frozen at  201C for a minimum of 2h. After centrifuging at
10000r.p.m.for10minagain,thesupernatantwasdiscardedandpelletwassaved.
Thepelletwasresuspendedinacetone,ﬁltered,anddriedon Whatmanﬁlters.MCP
Figure 5 Gal-3 overexpression reduced cisplatin-induced calpain activation in
LNCaP cells. Cells were treated with 50mM cisplatin for indicated times. (a) The
expression levels of Gal-3 in control LNCaP and Gal-3 overexpressing clones.
(b)Westernblotanalysisshowedthatcisplatinhadnoeffectontheexpressionlevel
of calpain 2. (c) Calpain activity as represented by western blot analysis of spectrin
150kD fragment. (d) Casein zymography to detect calpain activity. Puriﬁed
recombinant rat calpain 2 was used as the positive control. Numbers represent the
intensityofcalpain2.ThevalueofVCcellswassetas‘‘1’’.VC,cellstransfectedwith
control vector; #29–11 and #29–23, two Gal-3 overexpressing clones. Data are
representative of three independent experiments Figure 6 Calpain activation contributed to the proapoptotic effect of Gal-3
knockdown. Cells were pretreated with 20mM PD150606 for 30min and then
treated with 50mM cisplatin for 12h. (ai) Inhibitory effect of PD150606 on calpain
activity. Numbers represent the relative intensity of spectrin 150kD normalized
tob-actin.ThevaluesofsiGal3-11andsiGal3-19treatedwithcisplatinonlywereset
as ‘‘1’’. (aii) The effect of PD150606 on caspase-3 activation, PARP cleavage,
caspase-9 activation, and cytochrome c release. Numbers represent the relative
intensities of active caspase-3 and PARP 89kD normalized to b-actin. The values
of siGal3-11 and siGal3-19 treated with cisplatin only were set as ‘‘1’’.
(bi) Downregulation of calpain 2 expression by siRNA transfection. After 24h of
transfection, cells were treated with 50mM cisplatin for 12h. (bii) Calpain 2
knockdown attenuated cisplatin-induced caspase-3 activation and PARP cleavage.
Cellsweretreatedasthesamewayasbi.Numbersrepresenttherelativeintensities
of active caspase-3 and PARP 89kD normalized to b-tubulin. The values of siGal3-
11 and siGal3-19 with sicontrol transfection and cisplatin treatment were set as ‘‘1’’.
Data are representative of three independent experiments
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Cell Death and Diseasewas dissolved in de-ionized distilled water and 0.3% MCP was used as the working
concentration.
Cell culture. Human prostate cancer cells PC3 (ATCC CRL-1435) and LNCaP
(ATCC CRL-1740) were purchased from the American Type Culture Collection
(Manassas, VA, USA). Two Gal-3 knockdown transfectants of PC3 cells named as
siGal3-11 and siGal3-19, and one non-target control vector transfectant named as
VC were established as described in our previous study.
10 Two Gal-3 over-
expressing clones of LNCaP cells named as #29–11 and #29–23, and one non-
target control vector clone named as VC were kindly provided by Dr. Reuben Lotan
(University of Texas MD Anderson cancer center, Houston, Texas, USA).
PC3 and LNCaP cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
and RPMI 1640 medium, respectively, supplemented with 10% fetal bovine serum.
For transfectants, 200mg/ml G418 (Invitrogen) was added to the culture medium.
Immunoﬂuorescence. Cells were ﬁxed with 4% paraformaldehyde/PBS for
15min,permeabilizedwith0.2%TritonX-100/PBSfor 10min,blockedin1%bovine
serum albumin (BSA)/PBS for 30min and incubated with rat anti-Gal-3 antibody
(1:50)for1h,thenincubatedwith Texasred-conjugatedanti-ratantibody(1:2000,
ICN Biomedicals, Costa Mesa, CA, USA) for 1h in the dark. Cells were mounted in
gelvatolandphotographedatthesameparameterusingSonyDXC-979MD3CCCD
video camera (Tokyo, Japan) connected to an OLYMPUS BX40 microscope
(Melville, NY, USA).
Assessment of apoptosis
DNAladderingassay. Cellpelletswerelysed with TE/Tritonbuffer(10mMTris
(pH 8.0), 0.2% Triton X-100, 1mM EDTA) on ice for 10min, centrifuged at
13000 g for 15min at 41C. This lysis buffer is so mild that it cannot lyse nuclei,
so thesupernatantonly contains the low-molecular weight DNA fragmentsreleased
from nuclei; therefore, no high-molecular weight DNA is observed. The same
amount of supernatant was incubated at 371C for 1h with addition of 70mg/ml
RNase A, incubated at 501C for 2h with addition of 0.5% sodium dodecyl sulfate
(SDS) and 500mg/ml proteinase K, precipitated with ice-cold isopropanol,
centrifuged at 13000 g for 15min at 41C. DNA pellets were dissolved in
TEbuffer.DNAsolutionswererunona2%agarosegelcontaining100nMSYTO60
red ﬂuorescent nucleic acid stain (Invitrogen). The gel was scanned using Odyssey
infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA).
Cell viability assay. Cell viability was assessed by MTT as described
previously.
15 Cell survival of treated cells was represented as the percentage of
untreated control cells.
Detection of 89kD PARP and active caspase-3. Cells pellets were
lysedinRIPAbuffer(1%sodiumdeoxycholate,0.1%SDS,1%TritonX-100,50mM
Tris-HCl (pH 7.5) and 150mM NaCl) containing protease inhibitors. The resulting
cell lysate was analyzed by western blot using anti-PARP antibody and
anti-caspase-3 antibody.
DNA content assay by ﬂow cytometry. Brieﬂy, a total of 1 10
6 cells were
collected. After washing, cells were ﬁxed with 80% ethanol overnight at  201C,
washed with PBS, and treated with RNase A (1mg/ml) for 15min at 371C followed
by staining with propidium iodide (50mg/ml) (Sigma) for 15min at room
temperature. DNA content was analyzed using a Becton Dickinson FACScan
(Becton Dickinson, Franklin Lakes, NJ, USA).
Caspase activity assay. Caspase activity was measured using ﬂuorogenic
caspase substrates as described previously.
16 Cell pellets were lysed with cell
Figure 7 The blockage of Gal-3 by GCS-100/MCP enhanced cisplatin-induced
apoptosis in a calpain-dependent way. (ai) Cell viability assay by using MTT.
Columns (n¼3), mean; bars, ±S.D. ***Po0.001 compared with cisplatin
treatment only. (aii) Western blot analysis of active caspase-3. Numbers represent
the relative intensity of active caspase-3 normalized to b-actin. The value of control
cells was set as ‘‘1’’. Parental PC3 cells were pretreated with 0.3% MCP for 30min
and then cisplatin for 24h. (bi) Calpain activity as represented by western blot
analysis of spectrin 150kD. Numbers represent the relative intensity of spectrin
150kD normalized to b-actin. The value of control cells was set as ‘‘1’’. (bii) Casein
zymography to detect calpain activity. Puriﬁed recombinant rat calpain 2 was used
as the positive control. Numbers represent the intensity of calpain 2. The value of
control cells was set as ‘‘1’’. Parental PC3 cells were pretreated with 0.3% MCP for
30min and then cisplatin for 12h. (c) Western blot analysis of active caspase-3
showed that calpain 2 knockdown attenuated the proapoptotic effect of Gal-3
blockagebyGCS-100/MCP.ParentalPC3cellsweretransfectedwithsiRNAduplex
targetingcalpain 2 or non-target control siRNA. After 24h of transfection, cells were
pretreated with 0.3% MCP for 30min, and then treated with cisplatin (50mM) for
24h. Numbers represent the relative intensity of active caspase-3 normalized to
b-actin. The value of cells transfected with control siRNA plus cisplatin treatment
was set as ‘‘1’’. Data are representative of three independent experiments
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1mM EGTA, 1mM DTT, and 0.03% nonidet P-40) on ice for 30min. Lysates were
centrifuged at 15000 g for 10min at 41C, and 25mg of cell lysates were
incubated at 371C for 1h in a total volume of 100ml of caspase buffer (10mM
HEPES (pH 7.5), 50mM NaCl, and 2.5mM DTT) containing 35mM Ac-DEVD-AMC
or Ac-LEHD-AFC. Fluorescence upon cleavage of AMC or AFC by activated
caspases was monitored (excitation: 380nm for AMC and 400nm for AFC,
emission: 460nm for AMC and 505nm for AFC) using a Spectra Maxi Germini
ﬂuorescence plate reader (Molecular Devices, Sunnyvale, CA, USA).
Mitochondrial staining. Mitochondrial integrity was assessed by labeling
mitochondriausingamitochondrion-selectiveprobeaccordingtothemanufacturer’s
instruction. Brieﬂy, cells were incubated at 371C for 30min in growth medium
containing 100nM MitoTracker red CMXRos, ﬁxed with 3.7% formaldehyde in
growth medium at 371C for 15min. Then, cells were stained with 40, 6-diamidino-2-
phenylindole solution for 1min. Slides were mounted in gelvatol and photographed
at the same parameter using Sony DXC-979MD 3CCCD video camera connected
to an OLYMPUS BX40 microscope.
Cytochrome c release. Cells were lysed with mild cell extraction buffer
(20mM HEPES (pH 7.5), 1.5mM MgCl2, 10mM KCl, 1mM EDTA, 1mM EGTA,
4mM DTT, and 250mM sucrose) on ice for 1h. The lysates were then passed
through a 27
1/2-gauge syringe 10 times and centrifuged at 15000 g for 15min at
41C as described previously.
16 The resulting supernatant was analyzed by western
blot using mouse anti-cytochrome c antibody.
Caseinzymography. Calpain activity was measured by zymography usingits
enzyme substrate casein as described by Raser et al.
40 Brieﬂy, cell pellets were
lysed with mild cell extract buffer (20mM HEPES (pH 7.5), 10mM KCl, 1.5mM
MgCl2, and 250mM sucrose) containing protease inhibitors on ice for 30min, then
passed through a 27
1/2-gauge syringe 10 times, and incubated on ice for another
30min. Pure cytosolic fractions were cleared from cell lysate by ultracentrifugation
at 100000 g for 1h at 41C. To cast casein zymography gels, casein (0.2% w/v)
was copolymerized with 12% acrylamide, 0.32% bis-acrylamide, 375mM Tris-HCl
(pH 8.8) as the separating gel and 4% acrylamide, 0.11% bis-acrylamide, and
330mM Tris-HCl (pH 6.8) (no casein) as the stacking gel. The gel was pre-run at
130V for 30min at 41C in running buffer (25mM Tris base and 192mM glycine),
then 60mg of each sample mixed with 1/5 volume of sample buffer (150mM
Tris-HCl (pH 6.8), 20% glycerol, and 0.004% bromophenol blue) was loaded to the
gel, and run at 80V for 2h at 41C. After running, the gel was rinsed twice with
incubation buffer (20mM Tris-HCl, 10mM DTT, and 3mM CaCl2 (pH 7.5)) and
incubated at room temperature overnight. Finally, the gel was stained in 0.2%
commassie blue for 2h and destained in 5% methanol/8% acetic acid till sharp
transparent bands indicating calpain activity were visualized in blue background.
The gel was scanned using an Odyssey infrared image system (LI-COR
Biosciences, Lincoln, NE, USA). The quantiﬁcation of band intensity was per-
formed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Intracellular calcium analysis. Fluo-4 AM, a cell-permeant ﬂuorescent
calciumindicator,wasusedtoloadcellsaccordingtothemanufacturer’sinstruction.
Brieﬂy,cells were loaded with 1mM Fluo-4AM in loading medium (Hanks’ balanced
salt solution (HBSS)/1% BSA/0.02% pluronic F127/124mM sulﬁnpyrazone, pH 7.4)
for 30min at room temperature in the dark, washed twice in indicator-free medium
(HBSS/1% BSA/124mM sulﬁnpyrazone, pH 7.4), and then incubated in indicator-
free medium for another 30min. Finally, slides were mounted in gelvatol and
ﬂuorescent imageswereacquiredusingaSonyDXC-979MD3CCCDvideocamera
connected to Olympus BX40 microscope.
siRNAtransfection. siRNAtransfectionwas performedto knockdowncalpain
1/2accordingtothemanufacturer’sinstructionforTransIT-TKOtransfectionreagent
(Mirus Bio Corporation, Madison, WI, USA). After 24h of transfection, cells were
replaced with fresh growth medium and treated with related reagents.
Western blot analysis. Cells were lysed in RIPA buffer containing protease
inhibitors. Equal amounts of proteins were separated on SDS-polyacrylamide gel
electrophoresis gels and transferred to polyvinylidene ﬂuoride membranes
(Millipore, Bedford, MA, USA). Membranes were blocked in 0.1% casein/
0.2 PBS for 1h, incubated with appropriate primary antibodies for 2h, then
incubated with secondary antibodies conjugated with IRDye 800 (Rockland
Immunochemicals, Gilbertsville, PA, USA) or Alexa Fluor 680 (Invitrogen) for
40min. After primary and secondary antibodies incubation, membranes were
washed four times with TPBS (PBS with 0.1% Tween 20) at 5min intervals.
Immunoblots were visualized using an Odyssey Infrared Imaging System. The
quantiﬁcation of bands intensity was performed using ImageJ software.
Statistical analysis. Data are expressed as mean±S.D. of three inde-
pendent experiments and analyzed by one-way ANOVA test using SPSS 14.0
software (SPSS Incorporated, Chicago, IL, USA). Po0.05 was considered
statistically signiﬁcant.
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